Statistical analysis revealed significant differences in the overall OS rates, 2-year OS rates, 3-year OS rates, and overall EFS rates between the two groups of pediatric ALL patients (P < 0.05), indicating that CDKN2A/B deletion was associated with lower OS and EFS rates. The gene discussed is CDKN2A; the disease is acute lymphoblastic leukemia.